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Warfarin, acenocoumarol, and phenprocoumon are among the major anticoagulant drugs worldwide. Because of their low
therapeutic index and serious adverse reactions (ADRs), their wide use, and their varying kinetics and pharmacogenetic
dependence, it is of great importance to explore further possibilities to forecast the dose beyond conventional INR measurements.
Here, we describe particulars of the relative pharmacogenetic inﬂuence on the kinetics of these agents, the population distribution
of genetics risk groups, and novel data on clinical features with inﬂuence on dose requirement and ADR risk. The usefulness
of genetic information prior to and soon after start of therapy is also discussed. The current renewed focus on these issues is
caused not only because of new genetic knowledge and genotyping facilities but also because of the high rate of serious ADRs.
Application of these measures in the care of patients with anticoagulant therapy is important awaiting new therapeutic principles
to be introduced, which may take long time still.
1.Introduction
Warfarin,phenprocoumon,andacenocoumarolarethemost
used anticoagulants worldwide. It is a paradox that at
the same time these drugs are amongst the top 5 drugs
all categories causing most serious and fatal events. Their
therapeutic index is very low. The major reason is the
diﬃculty to tailor the dose according to the individual
dose requirement which varies widely between patients. Few
other drugs than warfarin have a broader therapeutic dose
window, 20–30-fold, possibly with exception for narcotic
analgesics.
There are a number of determinants of anticoagulant
dose requirement. Historically, it has been known for long
that a vitamin K containing diet has an inﬂuence on the
eﬃcacy of warfarin and other coumarins. It has also been
known for a long time that increasing age reduces the
dose needed to achieve a therapeutic anticoagulant eﬀect
through inhibition of coagulation factor synthesis [1]. Other
factors that are known to inﬂuence dose requirement include
concurrent medication, and body surface area [2–4].
2. Anticoagulation-RelatedHaemorrhage
We embarked upon a prospective study of patients in
need of anticoagulation because of atrial ﬁbrillation, deep
venous thrombosis, pulmonary emboli, and so forth [5].
In our prospective study, warfarin na¨ ıve patients consented
to donate a blood sample for genotyping at the start of
warfarin treatment. The study included 1523 patients. All
of them were monitored according to local clinical routines
at 40 diﬀerent study sites in Sweden. Warfarin bleedings
deﬁned according to WHO deﬁnition of severe adverse drug
reaction [6]a sw e l la so t h e ra d v e r s er e a c t i o n sw e r er e p o r t e d
to the study centre where the blood samples were stored
in a biobank sample collection. In this cohort of patients
starting treatment with warfarin, the incidence of ﬁrst-time
severe haemorrhage was 2.3 per 100 patient years (95%
conﬁdence interval 1.4–3.1). During a mean followup time
of 10 months, 1.8% of the included patients died and the
overall incidence of severe bleeding or death (all-cause) was
4.3 per 100 patient years (95% c.i. 3.2–5.5) (Figure 1). Our





































ite of severe bleeding and all-cause mortality in the warfarin-treated
WARG cohort [5].
Table 1: Predictors of severe bleeding in the warfarin-treated
WARG cohort [5].
Predictor HR of major bleeding
Age (years) 1.02 (0.98–1.06)
Male sex 2.8 (1.1–7.3)∗
Target INR 1.3 (0.03–50)
Warfarin dose requirement (mg/d) 0.97 (0.79–1.2)
Time outside INR interval (10th of time in
study)
1.2 (0.95–1.5)
Use of drugs interacting with warfarin 2.3 (1.1–4.9)∗
∗P <. 05.
earlier [7–9], probably because of the more strict criteria
stipulated by WHO and applied by us.
Although the incidence of bleeding was lower than that
seen in many older studies, it is evident that haemorrhagic
complications remain a major clinical problem in antico-
agulation with vitamin K antagonists. When investigating
potential predictors of severe bleeding in a multivariable
model (Table 1), we identiﬁed two factors signiﬁcantly
associated with this adverse outcome—male gender (HR =
2.8, 95% c.i. 1.1–7.3) and use of drugs potentially interacting
pharmacologically with warfarin (HR = 2.3, 95% c.i. 1.1–
4.9). The vastly increased risk in men was an unexpected
ﬁnding and previous studies have oppositely showed an
increased risk in female patients [8, 10, 11]. Although the
associationbetweentheuseofinteractingdrugsandbleeding
mayhavebeenanticipated,theevidenceofanoveralleﬀectof
the full spectrum of interacting drugs has been scarce prior
to our ﬁndings. The association remained even after several
yearsoftreatment(Figure 2)indicatingprevailingdiﬃculties





















































Figure 2: Cumulative incidence or severe bleeding in warfarin-
treated users and non-users of drugs potentially interacting with
warfarin. Data from the WARG cohort [5].
3. Pharmacogenetics of Anticoagulants
With the development of pharmacogenetics, the interest
was focused on enzymes catalysing the metabolism of
anticoagulants to see if there was a relation between dose
requirement and genetic polymorphisms in these genes.
Early studies [12, 13] demonstrated an important role of
CYP2C9 in the metabolism of warfarin, in particular the 7-
hydroxylation of the more active S-enantiomer.
Aithal et al. were among the ﬁrst to show a clinical
implication of the CYP2C9 polymorphism. They studied
hospitalised patients and found that low-dose requirement
was associated with CYP2C9∗2 and CYP2C9∗3a l l e l e s[ 14].
These ﬁndings have subsequently been conﬁrmed in numer-
ous clinical or experimental study settings [4, 15–18].
Many polymorphisms of CYP2C9 have been described.
The common CYP2C9∗2a n d∗3 allelic functional variants
have a compromised ability to catalyze the oxidation of
S-warfarin, with in vitro activities of only 12 and 5%,
respectively, for the homozygous mutant forms [19, 20].
Other enzyme members of the CYP2C family have some
catalyzing capacity albeit very little and of minor importance
for the clearance of S-warfarin.
The identiﬁcation and localisation of the VKORC1 gene
[21, 22] paved the way to studies that demonstrated a
profound dependence of warfarin dose on the polymorphic
VKORC1 gene [23–26]. Since warfarin targets the Vitamin
K epoxide reductase, it is conceivable that any functional
mutations in this gene will perturb the balance between
the inﬂuence of warfarin and vitamin K on the enzyme
activity. There are a number of such SNPs with strong
linkage disequilibirium. One of these SNPs is located in
the promoter region and usually included in studies of the
VKORC1 genetics and warfarin dose requirements, namely
−1639G>A(rs9923231)[25].TheAalleleisassociatedwithHuman Genomics and Proteomics 3
Table 2: Combined CYP2C9/VKORC1 genotype frequencies calculated from known allele frequencies in Caucasians.
CYP2C9 VKORC1 ∗1/∗1 (66%) ∗1/∗2 (19%) ∗1/∗3 (12%) ∗2/∗2 (1.4%) ∗2/∗3 (1.3%) ∗3/∗3 (0.50%)
B/B (36%) 23.8% 6.8% 4.3% 0.50% 0.47% 0.18%
A/B (49%) 32.3% 9.3% 5.9% 0.69% 0.64% 0.25%
A/A (15%) 9.9% 2.9% 1.8% 0.21% 0.20% 0.075%
the need of lower doses than the G allele. The association
is such that a homozygous carrier of the A allele requires a
warfarin dose approximately 50% of that of an individual
that is homozygous for the G allele [27]. Similar eﬀects
have been ascribed to the VKORC 1173C > T (rs9934438)
polymorphism. However, these two SNPs are in pronounced
linkage disequilibrium and are interchangeably used as tag
SNPs for diﬀerentiation between a low-dose haplotype A
(−1639A and 1173T) and a high-dose haplotype B (−1639G
and 1173C) [25]. Other SNPs have been independently
associated with altered warfarin dose requirements, but
their contribution to the interindividual variability is small
comparedtothe −1639G>Aand1173C>Tpolymorphisms
[28,29].Below,thehaplotypeA/Bnomenclaturewillbeused
to denote VKORC1 polymorphisms.
Candidate gene work with univariate regression analysis
of small samples has limited power to detect warfarin dose
association with allelic variants with weak inﬂuence [30].
However, multivariate regression improves this possibility.
Thus, both CYP2C9∗3a n d∗2 were statistically signiﬁcant
predictors of warfarin dose when data were corrected for
nongenetic and other dose predictors [30].
Genome-wide association studies (GWASs) are increas-
ingly applied within pharmacogenomics and in studies of
multiple gene factors behind certain diseases. This approach
was used by us in 1053 of 1523 patients of the WARG
cohort[31]andwass uﬃcientlypowered todetectagenome-
wide signiﬁcance of P<1.5 · 10
−7 for polymorphisms
with modest inﬂuence on therapeutic dose need. Univariate
regression analysis of each SNP analysed (n = 325,997)
disclosed just two important loci/SNP regions. They were
in the VKORC1 and CYP2C9 genes. However, multivariate
regression analysis also revealed another SNP although with
weaker association. This SNP is located in a gene encoding
a cytochrome P450 enzyme protein, CYP4F2, a putative
catalyst of Vitamin K1 oxidation [32].
4. TranslationintoClinicallyUseful Algorithms
The pharmacogenetic knowledge about warfarin pharma-
cokinetics and pharmacodynamics has to be translated into
usefuldosingguidelinesinordertobeacceptedintheclinical
care of patients in need of warfarin. Several algorithms
have been suggested on the basis of patient information
with or without genetic data on the VKORC1 and CYP2C9
polymorphisms. By now, there is unequivocal evidence that



















































































Figure 3: Combined CYP2C9 and VKORC1 genotype frequencies.
The striped bar (1/4 of the Caucasian population) indicates
individuals without any variant alleles (CYP2C9∗2, CYP2C9∗3o r
VKORC1 A), while the solid bars represent genotypes with one or
more variant alleles (3/4 of the population).
Considering the allele frequencies of CYP2C9 and
VKORC1, it is obvious that about 3/4 of the Caucasian pop-
ulation carry at least one allelic variant in these genes with
lower warfarin dose requirement (Figure 3). Table 2 demon-
strates the fractional distribution of diﬀerent haplotypes
based on the allele frequencies given for each of the genes.
When based on a multiple regression model that was
developed in the WARG material [4], the algorithm for
estimation of warfarin dose (Table 3) predicts a 12-fold dif-
ference between the extreme haplotypes in the upper left and
lower right corners of Table 2. According to our algorithm
(Table 3), this diﬀerence increases to 14-fold if the patients
are treated with three interacting drugs, demonstrating the
complexity of interactions between all predictors of the
warfarindose.Thisisbecausethedoserequirementdecreases
much less (−5%) for the CYP2C9∗1/∗1, VKORC1B/B com-
bination than for the CYP2C9∗3/∗3, VKORC1A/A genotype
(−18%).
Figure 4 demonstrates the eﬀect of genotype, sex, inter-
acting drugs, and age, alone or in diﬀerent combina-
tions, on warfarin dose requirement. This variation has
signiﬁcant clinical implications. It is obvious from ﬁgure
4 that any genetic variation in the two genes compared
to CYP2C9∗1/∗1, VKORC1B/B, all other parameters being
equal, causes more than 15–20% decrease in dose require-
ment. This feature corresponds to about 3/4 of the pop-



















































































































































































































































































































































































































































Figure 4: Warfarin dose predictions based on the patient’s sex, age, CYP2C9 and VKORC1 genotype, and use of interacting drugs. “Drugs”
refer to the number of concomitantly used drugs potentially interacting with warfarin, causing an increased INR (drugs lowering INR are
not included in the algorithm).
common patient characteristics is also shown, for example,
80versus50yearsofage,threeinteractingdrugsversusnone,
and so forth.
In the clinical setting, it is common that warfarin
treatmenthastobecommencedwithoutgeneticinformation
about the patient. Such information, if requested, is usually
not provided until the patient has already received 5–10
warfarin doses. The value of genetic information is expected
to decrease the later it is available and after one week the
information is considered irrelevant by some investigators.
However, data generated in a broad warfarin consortium
have demonstrated an additive informative value of genetic
data on VKORC1 and CYP2C9 even when it is obtained 7–9
days after the start of treatment [35]. Previous and ongoing
studies have found that after 4–6, 7–9, and 14 days of INR-
guided therapy, genotyping still improves the prediction of
maintenance dose by 4–15%, 2–14%, and 4%, respectively
[35–39]. Individual warfarin dose predictions based on






Other coumarin derivates such as phenprocoumon (PC) and
acenocoumarol (AC) are widely prescribed in continental
European countries and Latin America, whereas warfarin is
the drug of choice in US, UK, and the Scandinavian coun-
tries. There are major diﬀerences in the pharmacokinetics
of the coumarin-based anticoagulants. Thus, acenocoumarol
has a much shorter half-life (2–8 hours) as comparedHuman Genomics and Proteomics 5
Table 3: The WARG warfarin dose algorithm [4].
Coeﬃcients Estimate Standard error P-value
Intercept 9.46823 0.11867 <2 × 10−16
VKORC1 B/B 0
VKORC1 A/B −0.90112 0.04959 <2 × 10−16
VKORC1 A/A −2.01863 0.06799 <2 × 10−16
CYP2C9∗1/∗1 0
CYP2C9∗1/∗2 −0.50836 0.05811 <2 × 10−16
CYP2C9∗1/∗3 −0.97546 0.07077 <2 × 10−16
CYP2C9∗2/∗2 −1.10204 0.19767 3.0 × 10−8
CYP2C9∗2/∗3 −1.74761 0.20391 <2 × 10−16
CYP2C9∗3/∗3 −3.40061 0.33091 <2 × 10−16
Age, years −0.03686 0.00172 <2 × 10−16
Male sex 0
Female sex −0.27698 0.04682 4.2 × 10−9
Interaction, no. of drugs
that increase INR
−0.06992 0.01867 .001
The model predicts the square root of the dose; hence the dose (mg/week) is
obtained by squaring the result.
to warfarin (30–45 hours) or phenprocoumon (156–172
hours) [40]. The genetic contribution to variation in kinetics
and dose requirement is more pronounced for warfarin
than for acenocoumarol or phenprocoumon. On the other
hand, adjustment of warfarin dose is easier than that of
phenprocoumon because of its shorter half-life and short
time to achieve steady state.
CYP3A4andCYP2C9arethemajorcatalystsofthephen-
procoumon 7-hydroxylation, and therefore the polymorphic
CYP2C9 enzyme contributes less to the metabolism of
p h e n p r o c o u m o nc o m p a r e dt ow a r f a ri n[ 40, 41]. In addition,
a part of the drug is excreted directly via the kidneys
or the bile. Because of this diﬀerence, phenprocoumon is
sometimes preferred as an alternative in patients harboring
the CYP2C9∗2 or CYP2C9∗3 alleles which signiﬁcantly
compromise the metabolism of warfarin, and to a high
degree also acenocoumarol [42, 43].
Identiﬁcation of the vitamin K epoxide reductase C1
gene [21] paved the way to the identiﬁcation of functional
mutations in VKORC1 gene, both those conferring warfarin
resistance [22] and those causing an increase in warfarin
dose requirement [25]. A recent publication [44]c o m p a r e d
the relation between on one hand the VKORC1 and
CYP2C9 genotype, and on the other, the mean weekly dose
requirement for acenocoumarol and phenprocoumon. The
diﬀerence in weekly average dose for individuals carrying
VKORC1 AA and BB genotypes was approximately two-fold
(as for warfarin) for each of the drugs, with the highest doses
in the BB group. The average reduction in acenocoumarol
and phenprocoumon dose requirements in patients with
mutant variants of CYP2C9 included in their study was at
most 1/3 of the average dose in wild type individuals. These
results clearly demonstrate the diﬀerence in dependence
on the CYP2C9 genetic polymorphisms of these drugs as
compared to warfarin. Other genes of relevance for warfarin
disposition or vitamin K action were not found to have
any impact on the dose requirement of acenocoumarol and
phenprocoumon [44].
Although phenprocoumon is less dependent on CYP2C9
for its elimination compared to acenocoumarol, polymor-
phisms in CYP2C9 have been associated with an increased
risk of overanticoagulation and bleedings for both drugs
[45–48]. There is still limited information regarding the
potential impact of VKORC1 polymorphisms on the risk of
adverse outcomes in patients treated with acenocoumarol
or phenprocoumon. Nevertheless, the VKORC1 A haplotype
has been associated with an increased risk of overanticoagu-
lation (INR > 4) in patients treated with acenocoumarol and
with major bleeding in phenprocoumon-treated individuals
[49, 50].
In summary, the clinical use of coumarins is associated
with great risk of over- or underanticoagulation. The risk
of severe adverse reactions including fatal outcome is among
the highest known in drug therapy. It has been manageable
by virtue of INR monitoring but needs to be further
reduced. The new knowledge about genes important for the
metabolism and eﬀect of these drugs suggest genotyping
to be applied in the clinic since the future development of
anticoagulant therapy is uncertain even if new therapeutic
principles are on the way to be introduced. Ongoing large
clinical trials such as COAG (Clariﬁcation of Optimal Anti-
coagulation Through Genetics) and EU-PACT (The Euro-
pean Pharmacogenetics of Anticoagulant Therapy trial) will
further elucidate these important issues and it remains to be
seen if their results will modify our current opinion [51, 52].
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